secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061110
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO cuts 15% workforce, focuses on three lead gene therapies; Q3 net loss $61.9M
--------------------------------------------------------------------------------

- Workforce reduction of ~15%, expected $100M cost savings over two years; cash runway extended into H2 2025.
- Q3 revenue $28.9M (Zolgensma royalties $28.4M), net loss $61.9M ($1.41/share) vs $75.5M loss year ago.
- Lead programs: ABBV-RGX-314 (wet AMD/DR), RGX-202 (Duchenne), RGX-121 (MPS II); strategic alternatives for others.
- ABBV-RGX-314 suprachoroidal data: 89% risk reduction in vision-threatening events at one year for dose level 2.
- Cash $364.5M as of Sep 30, 2023, down from $565.2M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/0000950170-23-061110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/rgnx-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer